Zealand Pharma A/S (ZEAL) 2023年年度报告「NASDAQ」.pdf

《Zealand Pharma A/S (ZEAL) 2023年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Zealand Pharma A/S (ZEAL) 2023年年度报告「NASDAQ」.pdf（162页珍藏版）》请在三个皮匠报告上搜索。

1、Annual Report 2023Changing lives with next-generation peptide therapeuticsZealand Pharma A/SSydmarken 11DK-2860 SborgCompany reg.no.20045078Management reviewSee our pipeline Read more on page 15Follow usThe big picture 3Our business 12Sustainability:Our patients,people and operations 29Corporate Gov

2、ernance 45Consolidated financial statements 80Financial statements of the parent company 139Reports 156Other information 160Financial statementsObesity Read more on pages 16-18 Other supplementary reports 2023 Remuneration ReportZealand Pharma Annual Report 20232ContentsOur purpose 4Zealand Pharma a

3、t a glance 5Letter from the CEO and theChair 62023 Achievements 9Financial highlights and key figures 102024 Outlook and objectives 11The big pictureContentsThe big pictureOur businessSustainabilityCorporate governanceFinancial statementsZealand Pharma Annual Report 20233Our purposeOur ambitionis to

4、 be the worlds best peptide drug discovery and development company.Changing lives with next-generation peptide therapeuticsContentsThe big pictureOur businessSustainabilityCorporate governanceFinancial statementsZealand Pharma Annual Report 20234253Our strategy is to pursue global co-development and

5、 commercialization partnerships that complement and extend our capabilities to bring new medicine to patients with unmet medical needs.Employeesas of December 31,2023,with 80%in research and development and related functions.4R&D focus areas include becoming a key player in the fast-developing obesi

6、ty space leading in the rare diseases congenital hyperinsulinism and short bowel syndrome advancing potential treatment options for chronic inflammatory diseases and type 1 diabetes expanding our pipeline through in-house research and external opportunities25 years of expertise in peptide R&D with a